Y
Yanjie Zhao
Researcher at Capital Medical University
Publications - 20
Citations - 226
Yanjie Zhao is an academic researcher from Capital Medical University. The author has contributed to research in topics: Immunotherapy & Breast cancer. The author has an hindex of 6, co-authored 20 publications receiving 149 citations.
Papers
More filters
Journal ArticleDOI
Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study.
Ni Jiang,Guoliang Qiao,Xiaoli Wang,Michael A. Morse,William R. Gwin,Lei Zhou,Yuguang Song,Yanjie Zhao,Feng Chen,Xinna Zhou,Lefu Huang,Amy Hobeika,Xin Yi,Xuefeng Xia,Yanfang Guan,Jin Song,Jun Ren,Jun Ren,H. Kim Lyerly +18 more
TL;DR: Treatment of advanced pancreatic cancer with combined DC-CIK infusions and S-1 was safe, resulted in favorable PFS and OS, and modulated the peripheral blood immune repertoire.
Journal ArticleDOI
Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients’ preference-based study (PPPS)
Yanjie Zhao,Guoliang Qiao,Xiaoli Wang,Yuguang Song,Xinna Zhou,Ni Jiang,Lei Zhou,Hongyan Huang,Jing Zhao,Michael A. Morse,Amy Hobeika,Jun Ren,Jun Ren,Herbert Kim Lyerly +13 more
TL;DR: DC-CIK combined with chemotherapy administration resulted in numerically superior PFS and OS compared with monotherapy in advanced NSCLC.
Journal ArticleDOI
Overexpression of an Immune Checkpoint (CD155) in Breast Cancer Associated with Prognostic Significance and Exhausted Tumor-Infiltrating Lymphocytes: A Cohort Study.
Yu-Chen Li,Yu-Chen Li,Quan Zhou,Qingkun Song,Rui-Bin Wang,Shuzhen Lyu,Xiudong Guan,Yanjie Zhao,Jiangping Wu +8 more
TL;DR: Overexpression of CD155 was correlated with more proliferative cancer cells and a dysfunctional immune microenvironment, and might be a potential immunotherapy target for breast cancer.
Journal ArticleDOI
Immune correlates of clinical benefit in a phase I study of hyperthermia with adoptive T cell immunotherapy in patients with solid tumors.
Guoliang Qiao,Xiaoli Wang,Xinna Zhou,Michael A. Morse,Jiangping Wu,Shuo Wang,Yuguang Song,Ni Jiang,Yanjie Zhao,Lei Zhou,Jing Zhao,Yan Di,Lihong Zhu,Amy Hobeika,Jun Ren,Jun Ren,Herbert Kim Lyerly +16 more
TL;DR: Combining HT with ACT plus either CT or anti-PD-1 antibody was safe, generated clinical responses in previously treated advanced cancers, and promoted TCR repertoire diversity and favorable changes in serum IL-2, IL-4, TNF-α, and IFN-γ levels in clinical responders.
Journal ArticleDOI
Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments.
Yanjie Zhao,Ni Jiang,Qingkun Song,Jiangping Wu,Yuguang Song,Hongmei Zhang,Feng Chen,Lei Zhou,Xiaoli Wang,Xinna Zhou,Huabing Yang,Jun Ren,Herbert Kim Lyerly +12 more
TL;DR: In advanced cancer patients, continuous dendritic cell-cytokine induced killer cell infusions are capable of recovering cellular immunity, improving patient status and quality of life in those who are unresponsive to conventional cancer treatment.